Penumbra acquires 90% interest in MVI Health JV, launches thrombectomy devices

Penumbra (NYSE:PEN) said today it acquired 40% of the outstanding shares of virtual reality joint venture MVI Health from collaborator Sixense, boosting its interest to 90%, and said it launched the Penumbra Jet 7 and Jet D reperfusion catheters. The joint venture intends to commercialize healthcare applications of virtual reality technology, Alameda, Calif.-based Penumbra said, though more information on the specifics of the technology has not yet emerged. Penumbra said it paid $20 million to Sixense to acquire the additional 40% interest in a deal with contains an anti-dilution provision intended to allow Penumbra to issue additional MVI shares to Sixense with an aggregate value of up to $4.5 million, according to an SEC filing. The company also announced the launch of its Jet 7 and Jet D reperfusion catheters, which are part of its Penumbra aspiration-based thrombectomy system intended for stroke revascularization. The Jet 7 is the company’s seventh generation reperfusion catheters designed fro proximal large vessel occlusions, while the Jet D is designed specifically for distal occlusions. “The Jet 7 reperfusion catheter with its advanced tracking technology and large 0.072″ aspiration lumen is the most advanced device for stroke. In my clinical experience, I was able to easily and quickly navigate the Jet 7 through tortuous anatomy to the face of the clot and achieve full revascularization after a single pass. We know from our own published experience ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Catheters Vascular Penumbra Inc. Source Type: news